Novo Nordisk A/S vs PAGSEG Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while PAGSEG Inc trades at $9.61 (market cap $2.60B). The key difference: Novo Nordisk A/S is far larger — about 84.8× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (11.19%). Which is the better fit depends on your goals.
| NVO | PAGS | |
|---|---|---|
Market Cap | $220.53B | $2.60B |
Sector | Health | Technology |
52-Week High | $71.70 | $12.00 |
52-Week Low | $35.29 | $7.75 |
Enterprise Value | $239.49B | $10.23B |
Dividend Yield | 3.63% | 11.19% |
Trailing returns across standard periods
Latest headlines on both assets
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →